Clinical Trial Update: A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP [Phase 3]

View source ↗

Summary

A Phase 3 study to assess the efficacy and safety of Empasiprubart versus IVIg in adults with CIDP is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• Empasiprubart
• IVIG (intravenous immunoglobulin)

Snippet

Sponsor: argenx | Conditions: Chronic Inflammatory Demyelinating Polyneuropathy, CIDP | Phase 3 | Status: RECRUITING